A phase 2 clinical trial published in the journal CANCER has demonstrated that a single 25-mg dose of psilocybin, combined with structured psychological support, produces significant and sustained reductions in depressive and anxiety symptoms among cancer patients. Follow-ups two years post-treatment revealed that nearly 54% of participants maintained marked symptom improvement. The study underscores psilocybin's potential as a novel therapeutic option for managing major depressive disorder in oncology, addressing limitations of conventional antidepressants.